← Back
Data updated: Mar 29, 2026
EXTROVIS
OncologyInfectious DiseaseDermatology
Big Pharma
EXTROVIS is a major pharmaceutical company focused on Oncology, Infectious Disease, Dermatology.
1963
Since
15
Drugs
-
Trials
79
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
FLUOROURACIL 2026-02-10
Labeling
FLUOROURACIL 2026-02-10
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 40%
4 drugs
Infectious Disease 20%
2 drugs
Dermatology 20%
2 drugs
Respiratory 10%
1 drugs
Gastroenterology 10%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Gastroenterology, Respiratory
Baxter specialty
Infectious Disease, Oncology, Dermatology
Gilead Sciences biotech
Infectious Disease, Oncology, Gastroenterology, Respiratory
GSK big-pharma
Infectious Disease, Respiratory, Oncology
Active (13)
CALCIUM CHLORIDE 10% CLINDAMYCIN PALMITATE HYDROCHLORIDE TEMOZOLOMIDE PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AZITHROMYCIN FLUDARABINE PHOSPHATE IFOSFAMIDE CARAC LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE EFUDEX PROPRANOLOL HYDROCHLORIDE FLUOROURACIL METHOTREXATE SODIUM PRESERVATIVE FREE
Discontinued (2)
Company Info
- First Approval
- 1963-07-30
- Latest
- 2024-11-27
- Applications
- 15